Oxford Biomedica is an innovative, leading viral vector specialist with over 30 years of experience in the cell and gene therapy industry. The company is based in Oxfordshire, UK, with five facilities there, as well as two each in the U.S. and France. Oxford Biomedica works across key viral vector delivery systems, including those based on lentivirus, AAV, and adenovirus. Their industry-leading lentiviral vector platform LentiVector is used to develop product candidates in-house before seeking partners to take products to trial. The company also offers full-scope process development and GMP operations for AAV manufacturing.